Background: Small-cell lung cancer (SCLC) is a malignant tumor known for its poor prognosis. In addition to chemotherapy and immunotherapy irradiation plays a big role especially in inoperability. This study evaluated prognostic factors in patients with SCLC, receiving chemotherapy and thoracic irradiation, that may affect overall survival (OS), progression-free survival (PFS) and toxicity.
Methods: Patients with limited disease (LD) SCLC (n = 57) and extensive disease (ED) SCLC (n = 69) who received thoracic radiotherapy were analyzed retrospectively. The prognostic factors sex, age, Karnofsky performance status (KPS), tumor-, nodal-stage and timepoint of start of irradiation in relation to the first cycle of chemotherapy were evaluated. Start of irradiation was stratified as early ([Formula: see text] 2 cycles of chemotherapy), late (3 or 4 cycles) and very late ([Formula: see text] 5 cycles). Results were analyzed by Cox univariate and multivariate as well as logistic regression analysis.
Results: The median OS of LD-SCLC patients was 23.7 months in early, and 22.0 months in late start of irradiation. In very late start, median OS was not reached. PFS was 11.8, 15.2 and 47.9 months, respectively. In patients with ED-SCLC OS was 4.3 months in early, 13.0 months in late and 12.2 months in very late start of irradiation. PFS was 6.7, 13.0 and 12.2 months, respectively. Prognosis of patients with LD- or ED-SCLC receiving late or very late start of irradiation was significantly prolonged in OS and PFS compared to an early start (p < 0.05). KPS [Formula: see text] 80 shows a significant increase of OS and PFS in ED-SCLC. Female sex and smaller mean lung dose were associated with lower risk of toxicity.
Conclusion: Late or very late start of irradiation is a prognosis-enhancing factor in LD-SCLC and ED-SCLC for OS and PFS. KPS [Formula: see text] 80 increases prognosis of OS and PFS in ED-SCLC as well. Toxicity is less common in female sex and patients with low mean lung dose in LD-SCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114406 | PMC |
| http://dx.doi.org/10.1186/s13014-023-02252-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.
Endocr Oncol
January 2024
Department of Oncology, Department of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
Summary: Craniopharyngiomas (CPs) are rare brain epithelial tumours arising in the suprasellar region, infiltrating adjacent areas causing visual loss, panhypopituitarism, cognitive deficits and morbid obesity. Papillary CPs (PCPs) harbour in 94% BRAF mutation cases. Two patients with PCP and BRAF V600E mutations but with different tumour status were treated with BRAF and MEK inhibitors.
View Article and Find Full Text PDFFeasibility of a comprehensive supervised exercise program during and after treatment of head and neck cancer: a mixed-methods study.
Support Care Cancer
January 2025
Laboratory of Experimental Radiotherapy, Department of Oncology, University of Leuven, Louvain, Belgium.
Purpose: This study evaluates the feasibility of a comprehensive supervised exercise program (CSEP) for head and neck cancer (HNC) patients during and after (chemo)radiotherapy, integrating quantitative and qualitative data to identify participation barriers and facilitators.
Methods: To investigate the feasibility of the CSEP, a mixed-method study was performed. For the quantitative part, first, adherence to and safety of the CSEP were considered as quantitative feasibility outcome measures.
Progression of nutritional impact symptoms in cancer patients undergoing radiotherapy.
Support Care Cancer
January 2025
Department of Nutrition, Federal University of Paraná, Curitiba, Brazil.
Objectives: To analyze the presence of nutritional impact symptoms (NIS) throughout radiotherapy treatment in the head and neck, thorax, abdomen, and pelvis areas.
Methods: A prospective cohort study was conducted with individuals undergoing radiotherapy for cancer. Three assessments were carried out: at the start of radiotherapy, midway through, and in the last week of treatment.
Validation of clearcalc for efficient patient specific QA.
Med Dosim
January 2025
Medical Technology, Health Information and Research Directorate, Ministry of Health, Jerusalem, Israel.
Uganda's only radiotherapy center is a very busy facility treating about 210 patients daily on three linear accelerators making it sometimes hard to have machine time for pretreatment QAs. This study was aimed at validating an independent calculation software, ClearCalc (ICS) for second checks of the treatment planning system (TPS) calculations. The validation of ICS started with simple phantom test plans consisting of square, irregular, open and wedged fields designed in the TPS and measured in phantoms.
View Article and Find Full Text PDFDelays in chemotherapy and radiotherapy of breast cancer during COVID-19 pandemic.
J Infect Public Health
January 2025
Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Shahid Hemmat Highway, P.O Box: 14665-354, Tehran 1449614535, Iran.
Background: During the COVID-19 pandemic, hospitals were overwhelmed with infected patients, leading to a disruption in the delivery of services. Patients with cancer, including breast cancer, rely on timely treatment, as delays can reduce survival rates. In this study, we investigated delays in treatment and the factors contributing to delays in chemotherapy and radiotherapy for these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!